July 14, 2023 SARC037 is Open and Accruing In a rare disease as Ewing sarcoma, we recognize we need to work together to complete important studies like this. Read more
January 15, 2021 New Study in Ewing Sarcoma Open to Enrollment SARC037 is a phase I study protocol to determine the recommended dose of trabectedin given as a 1-hour infusion in combination with low dose irinotecan. All patients enrolled will receive trabectedin combination … Read more
November 30, 2020 Open Accruing SARC Studies Open accruing studies for you to refer or enroll your patients: SARC024 for Rhabdomyosarcoma (alveolar and embryonal) and Mesenchymal Chondrosarcoma SARC031 for Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve … Read more